AlzeCure Pharma AB (publ) announced that the board has appointed Martin Jönsson as new CEO. Current CEO Johan Sandin, who is also one of the founders of AlzeCure Pharma, remains in the company as Chief Scientific Officer (CSO) and will thus continue to be deeply involved in the research and development of the company's portfolio of candidate drugs. Martin Jönsson comes most recently from a senior position at Ferring Pharmaceuticals in the US, where for the past five years, among other things, he was business area director for a number of therapy areas.

He has extensive experience from various positions at both Ferring Pharmaceuticals and Roche, where he worked with business development, in- and out-licensing of pharmaceuticals, marketing and sales, and alliance management. Martin Jönsson will become CEO of AlzeCure with effect from January 9, 2020.